Drug intelligence / Profile preview

SNS-723

Development stage: Preclinical
Lead developer: Sensei Biotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SNS-723 is a first-in-class chimeric antigen receptor (CAR) T-cell therapy targeting human aspartate β-hydroxylase (ASPH). Developed by Sensei Biotherapeutics, it utilizes a high-affinity single-chain variable fragment (scFv) derived from an anti-ASPH monoclonal antibody to direct T-cells against tumor cells. ASPH is a cell surface enzyme primarily expressed during fetal development but highly overexpressed in various solid tumors, making it a promising target for precision immuno-oncology. The therapy is designed to provide effective tumor targeting while minimizing off-target toxicities to healthy tissues.

Targets

ASPH (Aspartyl/asparaginyl beta-hydroxylase)

Beyond the preview

Go deeper on SNS-723.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNS-723.

Explore the full profile